(Q31440135)

2 July 2017

1 reference

title

Zaleplon: a review of its use in the treatment of insomnia (English)

1 reference

2 July 2017

0 references

1 reference

M Dooley

1

1 reference

2 July 2017

G L Plosker

series ordinal

2

1 reference

2 July 2017

language of work or name

1 reference

1 August 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

60

1 reference

2 July 2017

issue

2

1 reference

2 July 2017

page(s)

413-445

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060020-00014

2 July 2017

exact match

0 references

cites work

A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200060020-00014

Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue

21 January 2018

1 reference

12 December 2020

Use and abuse of the benzodiazepines

1 reference

12 December 2020

Polysomnographic effects of hypnotic drugs. A review

1 reference

12 December 2020

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

1 reference

12 December 2020

Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.

1 reference

12 December 2020

Identification of sleep-promoting neurons in vitro.

1 reference

12 December 2020

Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

1 reference

12 December 2020

Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia

1 reference

12 December 2020

A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening

1 reference

12 December 2020

Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia

1 reference

12 December 2020

Clinical management of patients with insomnia. The role of zopiclone

1 reference

12 December 2020

Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects

1 reference

12 December 2020

Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.

1 reference

12 December 2020

The effects of new hypnotic drugs in rats trained to discriminate ethanol

1 reference

12 December 2020

Management of insomnia

1 reference

12 December 2020

Zaleplon and triazolam in humans: acute behavioral effects and abuse potential

1 reference

12 December 2020

Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia

1 reference

12 December 2020

A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.

1 reference

12 December 2020

The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers.

1 reference

12 December 2020

Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of the cyclic alternating pattern.

1 reference

12 December 2020

Rapid disappearance of zaleplon from breast milk after oral administration to lactating women.

1 reference

12 December 2020

Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

1 reference

12 December 2020

Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846

1 reference

12 December 2020

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group

1 reference

12 December 2020

Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia

1 reference

12 December 2020

Absence of an interaction between ibuprofen and zaleplon.

1 reference

12 December 2020

Zaleplon pharmacokinetics and absolute bioavailability

1 reference

12 December 2020

Insomnia. Use of a 'decision tree' to assess and treat.

1 reference

12 December 2020

Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II.

1 reference

12 December 2020

The direct economic costs of insomnia in the United States for 1995.

1 reference

12 December 2020

Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem

1 reference

12 December 2020

Psychomotor effects of zaleplon and thioridazine coadministration

1 reference

12 December 2020

10.2165/00003495-200060020-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

2 July 2017

1014867647

0 references

1 reference